NCT07163325 - EP102 Safety and Efficacy in METTL3 Modulation in Advanced Solid Tumors | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 24, 2025

Primary Completion Date

November 30, 2027

Study Completion Date

November 30, 2028

Conditions

Advanced Solid Tumor (Phase 1)

Interventions

DRUG

EP102

EP102 will be administered orally

Trial Locations (8)

RECRUITING

Institut Jules Bordet, Brussels

RECRUITING

Cliniques universitaires Saint-Luc, Brussels

RECRUITING

Hospital Universitari Vall d'Hebron - Vall d'Hebron Institute of Oncology, Barcelona

RECRUITING

Hospital Universitario de Santiago de Compostela, Santiago de Compostela

RECRUITING

START Madrid - CIOCC, Madrid

RECRUITING

Olomouc University Hospital, Olomouc

RECRUITING

Masaryk Memorial Cancer Institute, Brno

RECRUITING

Netherlands Cancer Institute (NKI), Amsterdam